Cordex Receives Special Protocol Assessment Approval for ATPace

Cordex Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the design of pivotal, Phase 2b/3 clinical trials evaluating its lead product ATPace as an antiarrhythmic drug for the acute treatment of patients with paroxysmal supraventricular tachycardia under the Special Protocol Assessment process.
CNN Money